초록 ▼

A pharmaceutically acceptable implant system comprising a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles having a radioopaque agent covalently attached to a plurality of the particles in the collection, with the radioopaque agent being present in the collection

A pharmaceutically acceptable implant system comprising a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles having a radioopaque agent covalently attached to a plurality of the particles in the collection, with the radioopaque agent being present in the collection at a concentration of at least about 0.1% w/w. The implantable materials may be used, for instance, in an iatrogenic site and for fiducial marking.

대표청구항 ▼

1. A pharmaceutically acceptable implant system comprising: a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles having a radioopaque agent covalently attached to a plurality of the particles in the collection,with the radioopaque agent being present in the collecti

1. A pharmaceutically acceptable implant system comprising: a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles having a radioopaque agent covalently attached to a plurality of the particles in the collection,with the radioopaque agent being present in the collection at a concentration of at least about 0.1% w/w. 2. The system of claim 1 with the hydrogel particles comprising the covalently attached radiopaque agent being a first set of particles, andfurther comprising a second set of particles comprising particles free of a covalently-bound radioopaque agent. 3. The system of claim 1 wherein the hydrogel particles are spheroidal with a maximum diameter of between about 20 to about 200 microns. 4. The system of claim 1, with the hydrogel particles being biodegradable to produce only degradation products that are absorbed into the circulatory system and cleared from the body via renal filtration. 5. The system of claim 4 with the hydrogel particles being hydrolytically biodegradable. 6. The system of claim 5 wherein the hydrogel particles, before hydrolysis, have a total swellability in physiological solution of no more than about 30% by volume. 7. The system of claim 1 wherein degradation products of the hydrogel particles comprise a polyethylene glycol covalently bound to the radioopaque agent, with the radioopaque agent comprising iodine. 8. The system of claim 1 wherein the hydrogel is a product of a covalent crosslinking chemical reaction between at least two precursors, with one of the precursors comprising a branched polyethylene glycol with at least four arms. 9. The system of claim 8 wherein between 25% and 90% of the arms comprise the radioopaque agent. 10. The system of claim 1 with the collection having a lubricity and maximum diameter for manual passage out of a syringe through a 30 gauge needle. 11. The system of claim 10 further comprising an osmotic agent that comprises a linear hydrophilic polymer, with the agent present in a mixture with the collection. 12. The system of claim 1 wherein the collection of particles is completely biodegradable at a time between about 30 and about 365 days. 13. The system of claim 12 wherein the collection comprises a plurality of sets of the particles, with the sets having different rates of biodegradation. 14. The system of claim 13 wherein a first set of the particles is biodegradable within about 8 to about 12 days and a second set of the particles is degradable within about 45 to about 55 days. 15. The system of claim 1 wherein the particles are hydrolytically degradable. 16. The system of claim 1 wherein a plurality of the particles are not biodegradable. 17. The system of claim 1 further comprising an applicator, with the particles being disposed in the applicator. 18. The system of claim 17 wherein the particles are dehydrated. 19. The system of claim 18 further comprising a container of physiological saline fluidly connectable to the applicator to mix the saline and particles in the applicator. 20. The system of claim 1 further comprising a therapeutic agent. 21. The system of claim 1 further comprising a radiation source. 22. The system of claim 1 wherein the crosslinked hydrogels comprise a first precursor and a second precursor covalently bonded to each other wherein the first precursor, before crosslinking, comprises a branched polyethylene glycol with at least four arms and between 25% and 90% of the arms comprising the radioopaque agent.